Mandate

Vinge advises the Swedish Government in connection with the sale of Vectura Consulting AB

June 18, 2013

Vinge is advising the Swedish Government in connection with the sale of Vectura Consulting AB to Sweco AB (publ) for SEK 927 million. The sale is subject to approval by the Swedish and Norwegian competition authorities and is estimated to be completed during the summer of 2013.

Vectura has been a fully state-owned subsidiary since 2009 following the merger of the Swedish Road Administration’s Consultancy Services division and the Swedish Rail Administration’s Engineering Services division. The Government’s sale is taking place in light of the fact that Ventura conducts operations on a market exposed to effective competition, without a specific public service mandate.

Ventura provides consultancy services relating to transport infrastructure planning in Sweden, Norway and Denmark and had a turnover of approximately SEK 1.3 billion in 2012. The company has approximately 1,200 employees and is the market leader in Sweden within the transport infrastructure field with customers at approximately 40 locations in Sweden. Sweco, which is listed on Nasdaq OMX Stockholm, is an international consultancy company providing engineering, environmental and architectural services. Sweco has an annual turnover of approximately SEK 7.5 billion and has approximately 7,800 employees in the Nordic region as well as Central and Eastern Europe. 

Vinge’s team consists of partners Carl Gustav De Geer and Daniel Rosvall together with associates Nina Farrahi and Sofie Bjärtum. Specialist advice is being provided by Maria Schultzberg, Fredrik Gustafsson and Peter Alstergren.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026